Impact of the South Korea-US Free Trade Agreement on the Korean pharmaceutical industry | Practical Law

Impact of the South Korea-US Free Trade Agreement on the Korean pharmaceutical industry | Practical Law

This chapter analyses the provisions of the South Korea-US Free Trade Agreement (FTA), which was signed by South Korea and the US on 30 June 2007 and will take effect on 15 March 2012. It looks at the FTA in terms of the adoption of the independent review process in the pharmaceutical sector, the introduction of the approval-patent linkage system, data exclusivity, customs duties and non-tariff barriers and competition law.

Impact of the South Korea-US Free Trade Agreement on the Korean pharmaceutical industry

by Chul Ho Kim and Jiyul Yoo, Yoon & Yang LLC
Law stated as at 01 Nov 2011 • South Korea, USA (National/Federal)
This chapter analyses the provisions of the South Korea-US Free Trade Agreement (FTA), which was signed by South Korea and the US on 30 June 2007 and will take effect on 15 March 2012. It looks at the FTA in terms of the adoption of the independent review process in the pharmaceutical sector, the introduction of the approval-patent linkage system, data exclusivity, customs duties and non-tariff barriers and competition law.
This article is part of the PLC multi-jurisdictional guide to life sciences. For a full list of jurisdictional Q&As visit www.practicallaw.com/lifesciences-mjg.